| Systematic (IUPAC) name | |
|---|---|
| 4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| MedlinePlus | a610012 |
| Pregnancy cat. | C(US) |
| Legal status | ℞ Prescription only |
| Routes | Oral, topical (eye drops) |
| Pharmacokinetic data | |
| Bioavailability | High (oral) Minimal (topical) |
| Protein binding | ~55% |
| Excretion | Renal (75–90%) |
| Identifiers | |
| CAS number | 125602-71-3 |
| ATC code | None |
| PubChem | CID 2350 |
| DrugBank | DB04890 |
| ChemSpider | 2260 |
| UNII | HYD2U48IAS |
| KEGG | D09705 |
| ChEMBL | CHEMBL1201758 |
| Chemical data | |
| Formula | C21H25ClN2O3 |
| Mol. mass | 388.88 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Bepotastine (Talion) is an antihistamine. It was approved in Japan for use in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name TALION. TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. Senju, in turn, has granted the US rights for the ophthalmic preparation to ISTA Pharmaceuticals, Inc., a specialty pharmaceutical company located in Irvine, CA.